Quantum dot immunohistochemistry was exploited to detect Mina53, Ki67 and P53 expression in pancreatic cancer. To explore the role of Mina53 in human pancreatic cancer, we analysis the relationship of Mina53 expression with clinical and pathological features, tumor suppressor gene (P53) and tumor proliferative

activity. Results: Mina53 expression mainly located in the cell nucleus, there may also be a small number of cytoplasmic expression. There only two cases of positive expression of 34 cases of normal pancreatic tissue, and the two cases are weakly expression, the positive rate was 5.9%; 81 were positive in a total of 96 cases of pancreatic cancer, the positive rate was 84.4%, of which 13

cases +, 39 cases + +, 29 cases + + +, 15 cases -. Mean rates of positive cell is 49.81 ± 19.67% (X ± s). Then the expression of Mina53 in pancreatic cancer was significantly higher RAD001 ic50 than that of normal pancreatic tissue (P < 0.01). Relationship between Mina53 expression and pancreatic cancer clinicopathological features: Mina53 expression in pancreatic cancer was unrelated with gender, age, and distant node metastasis (P > 0.05). Mina53 expression increased with the progression of clinical stage. INCB024360 The respective periods of Mina53 expression rate is distinctive (χ2 = 8.446, (P < 0.01), which is also associated with tumor tissue differentiation degree (χ2 = 4.992, P < 0.05) and lymph node metastasis (χ2 = 5.667, P < 0.05). P53 and Ki67 in pancreatic cancer are nuclear expression. P53 is positive else in 80 cases (83.3%), of which Mina53 (+) / P53 (+) are 76 cases, Mina53(+)/P53(−) are 5 cases, Mina53(−)/P53(+) are 4 cases, Mina53 (−) / P53 (−) are 11 cases. In pancreatic

cancer Mina53 expression and P53 protein accumulation was significantly correlated (χ2 = 41.102, P < 0.01). The LI mean value of Ki67 in Pancreatic cancer is 46.9 ± 19.1% (X ± s), which range is 11.7%−70.2%. Mina53 expression was positively correlated Ki67 LI value (r = 0.727, P < 0.01). Conclusion: Mina53 may play an important role in the biological behavior of pancreatic malignant transformation, invasion and metastasis. Key Word(s): 1. Mina53; 2. Ki67; 3. RNA interference; 4. immunohistory; Presenting Author: JOSEGUILLERMO DE LA MORA LEVY Additional Authors: ANGELICAIZTACIHUATL HERNANDEZ GUERRERO Corresponding Author: JOSEGUILLERMO DE LA MORA LEVY Affiliations: Instituto Nacional de Cancerología; Instituto Nacional de Cancerologia Objective: Metastases to the pancreas are clinically uncommon; however in a practice with a high volume of pancreatic EUS cases, a higher percentage are identified. The most common tumor to metastasize is renal cell carcinoma in most series. Our aim was to describe the endosonographic and some clinical features of a series of patients with pancreatic metastases.